First, our commercial organization continues to deliver attractive organic ... which was accepted for review by the FDA and assigned a February 28 PDUFA date. And lastly, on the business development ...

National Institutes of Health officials launched an internal review on rebuilding trust with people in the United States as ...

U.S. treatment session revenue for the three months ended September 30, 2024 was $13.3 million, an increase of 2% compared to $13.1 million in the third quarter of 2023. In the third quarter of 2024, ...

CENDIFOX: Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers. The trial has completed ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

There was a slight delay in the ABS-301 program due to issues at the contract research organization (CRO), affecting ... It's a traditional drug creation partnership structure.

On October 22, 2024, U.S. Customs and Border Protection (CBP) released data about what happened at the U.S.-Mexico border ...

When residents living near White Bear Avenue gathered this week at St. Pascal Baylon Catholic Church to discuss the 53-unit ...

This is evidenced by results gathered and published on arXiv.org using Benchpress ... are exploring algorithms for electronic ...

FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and ...

The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s ...